deltatrials

Chronic spontaneous urticaria Trials in Toronto, Canada

Conditions / Chronic spontaneous urticaria / Toronto, Canada

Chronic spontaneous urticaria is a medical condition with active clinical research programs worldwide.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID Title Status Phase
NCT05032157 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines COMPLETED PHASE3
NCT04210843 Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab TERMINATED PHASE3
NCT05513001 An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib ACTIVE_NOT_RECRUITING PHASE3
NCT03580369 A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines COMPLETED PHASE3
NCT02649218 A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients COMPLETED PHASE2
NCT02477332 Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU COMPLETED PHASE2
NCT06455202 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) ACTIVE_NOT_RECRUITING PHASE3
NCT04180488 Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) COMPLETED PHASE3
NCT06077773 Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria TERMINATED PHASE2
NCT06445023 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria ACTIVE_NOT_RECRUITING PHASE3

Related Pages